Short Interest in LivaNova PLC (NASDAQ:LIVN) Grows By 32.7%

LivaNova PLC (NASDAQ:LIVN) saw a large growth in short interest in January. As of January 30th, there was short interest totaling 2,436,767 shares, a growth of 32.7% from the January 15th total of 1,836,041 shares. Currently, 4.5% of the shares of the company are sold short. Based on an average daily trading volume, of 603,535 shares, the days-to-cover ratio is presently 4.0 days. Based on an average daily trading volume, of 603,535 shares, the days-to-cover ratio is presently 4.0 days. Currently, 4.5% of the shares of the company are sold short.

LivaNova Trading Up 3.0%

NASDAQ:LIVN opened at $65.80 on Monday. The firm has a market capitalization of $3.59 billion, a P/E ratio of -16.45 and a beta of 0.97. The company has a quick ratio of 1.12, a current ratio of 1.33 and a debt-to-equity ratio of 0.30. The company has a fifty day moving average of $63.62 and a 200 day moving average of $57.60. LivaNova has a 52 week low of $32.48 and a 52 week high of $67.92.

Institutional Investors Weigh In On LivaNova

Large investors have recently made changes to their positions in the business. Primecap Management Co. CA lifted its stake in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 4,641,352 shares of the company’s stock worth $208,954,000 after acquiring an additional 32,942 shares during the period. Millennium Management LLC boosted its position in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock valued at $155,559,000 after acquiring an additional 544,033 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in LivaNova by 94.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock valued at $127,129,000 after acquiring an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of LivaNova by 83.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock worth $122,858,000 after acquiring an additional 1,067,349 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of LivaNova by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after acquiring an additional 34,812 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on LIVN shares. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Barclays upped their target price on LivaNova from $58.00 to $67.00 and gave the stock an “equal weight” rating in a research note on Friday, January 9th. KeyCorp began coverage on LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 price target for the company. Stifel Nicolaus boosted their price target on shares of LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $69.38.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.